Changes in Plasma Anti-Annexin A5 Antibody After Acute Myocardial Infarction

Document Type : Original Article


1 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, IR Iran.

2 Research Center for Non-Communicable Diseases, Jahrom University of Medical Sciences, Jahrom, IR Iran.

3 Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, IR Iran.

4 Department of Biochemistry, Department of Advanced Medical Sciences and Technologies, Research Center for Non-Communicable Diseases, Jahrom University of Medical Sciences, Jahrom, IR Iran.


Background: Anti-annexin A5 antibodies (aANVAs) are thought to have the capacity to cause thrombosis and to be a risk factor for cardiovascular diseases. The present study aimed to detect changes in aANVAs in acute myocardial infarction (AMI) on admission and 10, 40, and 70 days after the acute phase.
Methods: Forty-five patients with confirmed AMI were selected for analysis. Plasma aANVAs were measured by enzyme-linked immunosorbent assay (ELISA) on admission and 10, 40, and 70 days after AMI.
Results: Significant positive cases of aANVAs were observed during the follow-up (P<0.001). The positive cases of aANVAs were more during a 70-day period than on admission (P=0.004) and 10 days (P=0.008) and 40 days (P=0.016) following AMI. No significant increase was found in the plasma concentration of aANVAs during the follow-up (P>0.05).
Conclusions: A significant increase was observed in aANVAs-positive cases on the 70th post-AMI day. The increase may indicate the existence of a hyperactive coagulopathy state during this period. (Iranian Heart Journal 2022; 23(3): 69-76)


  1. Qin C, Yang YH, May L, Gao X, Stewart AG, Tu Y, et al. Cardioprotective potential of annexin-A1 mimetics in myocardial infarction. Pharmacology & therapeutics 2015; 148:47-65.
  2. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New England Journal of Medicine 1995; 332 (10):635-641.
  3. Jansson J, Nilsson T, Johnson Ov. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998; 80 (4):334-337.
  4. Rand JH, Wu X-X, Andree HA, Ross JA, Rusinova E, Gascon-Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood, The Journal of the American Society of Hematology 1998; 92 (5):1652-1660.
  5. Schanberg L. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.: Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis rheum 2009; 60:1496-1507.
  6. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsperger C, de Groot PG. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arteriosclerosis and thrombosis: a journal of vascular biology 1994; 14 (5):824-830.
  7. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96 (7):2339-2347.
  8. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. Journal of nuclear medicine 2005; 46 (12):2035-2050.
  9. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arteriosclerosis, thrombosis, and vascular biology 2009; 29 (7):1031-1038.
  10. Matsuda R, Kaneko N, Kikuchi M, Chiwaki F, Toda M, Ieiri T, et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation 2003; 57 (2):171-177.
  11. Hofstra L, Liem H, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. The Lancet 2000; 356 (9225):209-212.
  12. de Jong RC, Pluijmert NJ, de Vries MR, Pettersson K, Atsma DE, Jukema JW, et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. Scientific reports 2018; 8 (1):1-10.
  13. Matsuda J, Gotoh M, Saitoh N, Gohchi K, Tsukamoto M, Yamamoto T. Anti-annexin antibody in the sera of patients with habitual fetal loss or preeclampsia. Thrombosis research 1994; 75 (1):105-106.
  14. Zammiti W, Mtiraoui N, Kallel C, Mercier E, Almawi WY, Mahjoub T. A case-control study on the association of idiopathic recurrent pregnancy loss with autoantibodies against β2-glycoprotein I and annexin V. Reproduction 2006; 131 (4):817-822.
  15. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti‐annexin V antibodies in patients with systemic lupus erythematosus. American journal of hematology 1997; 54 (3):209-213.
  16. Sugiura K, Muro Y. Anti-annexin V antibodies and digital ischemia in patients with scleroderma. The Journal of rheumatology 1999; 26 (10):2168-2172.
  17. Tripathy N, Sinha N, Nityanand S. Anti‐annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity. Clinical & Experimental Immunology 2003; 134 (2):360-364.
  18. Emad Y, Sayed S, El-Azkalany GS, El-Fishawy HS, El Latif EA, Eissa AH. Relation of anti-annexin V antibodies to disease manifestations and activity in Behҫet’s disease patients. The Egyptian Rheumatologist 2018; 40 (1):51-54.
  19. Кравчун ПГ, Граматюк ГМ, Граматюк С. The study to measure the level of serum annexin V in patients with renal hypertension. 2015.
  20. Bakar F, Ünlütürk U, Başkal N, Nebioğlu S. Annexin V expression and anti-annexin V antibodies in type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism 2014; 99 (3):932-937.
  21. Gašperšič N, Rot U, Čučnik S, Kveder T, Božič B, Rozman B. Anti-annexin V antibodies in patients with cerebrovascular disease. Annals of the rheumatic diseases 2003; 62 (2):188-189.
  22. Shojaie M, Sotoodah A, Roozmeh S, Kholoosi E, Dana S. Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thrombosis journal 2009; 7 (1):13.
  23. Roldán V, Marín F, Pineda J, Marco P, Corral J, Climent V, et al. Anexina V en pacientes supervivientes de un infarto de miocardio prematuro. Revista Española de Cardiología 2002; 55 (12):1230-1234.
  24. Yeatman T, Updyke T, Kaetzel M, Dedman J, Nicolson G. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clinical & experimental metastasis 1993; 11 (1):37-44.
  25. Esposito G, Tamby MC, Chanseaud Y, Servettaz A, Guillevin L, Mouthon L. Anti-annexin V antibodies: are they prothrombotic? Autoimmunity Reviews 2005; 4 (1):55-60.
  26. Ogawa H, Zhao D, Dlott JS, Cameron GS, Yamazaki M, Hata T, et al. Elevated anti–annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. American journal of clinical pathology 2000; 114 (4):619-628.
  27. Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. The Journal of rheumatology 2000; 27 (4):924-929.
  28. Lieby P, Poindron V, Roussi S, Klein C, Knapp AM, Garaud JC, et al. Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 2004; 104 (6):1711-1715.
  29. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bulletin of the World Health Organization 2005; 83:820-829.
  30. Frostegård AG, Su J, von Landenberg P, Frostegård J. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease. Scandinavian journal of rheumatology 2010; 39 (1):77-83.